Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
Monotherapy with DPP-IV inhibitors, SGLT-2 inhibitors or insulin secretagogues frequently
failed to maintain blood glucose in patients with type 2 diabtes. It was critical to
determine which was more suitable of acarbose versus metformin plus pioglitazone.
Phase:
Phase 3
Details
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University